Drugs / eryaspase
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04292743 | Dec 2020 → Jan 2023 | pancreatic ductal adenocarcinoma | Georgetown University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03674242 | Jun 2019 → Mar 2022 | triple-negative breast carcinoma | ERYtech Pharma | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03665441 | Sep 2018 → Aug 2021 | pancreatic ductal adenocarcinoma | ERYtech Pharma | Completed | Missed primary |
| Phase not stated1 trial | ||||||
| — | NCT02197650 | — | acute lymphoblastic leukemia | ERYtech Pharma | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eryaspase | “eryaspase” NCT02197650 ↗ |
| Modality | Protein / enzyme biologic | “Erythrocytes encapsulating L-asparaginase” NCT02197650 ↗ |
| Route | Intravenous | “eryaspase 100 U/kg intravenously on days 1 and 15” PMID 41187298 ↗ Nov 2025 |